Category Archives: Indian Patent Law

The pill that costs $9,000 in US sells for $70 in India

Rema Nagarajan, TNN | Feb 7, 2016 And that’s just one leukaemia drug. India’s generic industry has been producing many such life-saving medicines at a fraction of the global price The Hyderabad-based Bharat Biotech might be the first to come out … Continue reading

Posted in Hepatitis C, Indian Patent Law, Sofosbuvir, Uncategorized | Leave a comment

Why India must beware the side-effects of Pacific Treaty

December 30, 2015, The Hindu Businessline | ARCHANA JATKAR The scope of the recently concluded Trans-Pacific Partnership Agreement (TPPA) goes well beyond conventional trade concerns. It includes extensive obligations on intellectual property (IP) exceeding the minimum standards of the World … Continue reading

Posted in Patent linkage, Patent Term Extension, Sec 3 (d), TPP, TRIPS flexibilities, Uncategorized | Leave a comment

No respite for Big Pharma on patents

FINANCIAL EXPRESS| By Banikinkar Pattanayak on December 30, 2015 Dilution of Section 3(d), compulsory licensing unlikely despite US concerns Disappointed with India’s new National IPR Policy, the US has upped the ante for a world-class patenting regime in India, but … Continue reading

Posted in Compulsory Licensing, IPR policy, Sec 3 (d), TRIPS, TRIPS plus, US pressure on India | Tagged , , , , , | Leave a comment

Delhi HC upholds Roche’s patent claims on Tarceva against Cipla

Economic Times, November 28, 2015. Mumbai – A division bench of the Delhi High Court sided with Roche against Indian firm Cipla, upholding the Swiss drug maker’s patent claims on key lung cancer drug erlotinib hydrochloride, branded Tarceva. The ruling is … Continue reading

Posted in Cancer, Patent infringement, Sec 3 (d) | Leave a comment

Drug patenting in India: looking back and looking forward

Nature reviews. By Bhaven N. Sampat and Kenneth C. Shadlen. Patent protection for drugs in India has been a contentious issue in recent years, with several high-profile denials of patents — for example, for Novartis’ anticancer drug imatinib mesylate (Glivec; also … Continue reading

Posted in Indian Patent Law, Patents, Sec 3 (d) | Leave a comment

India – IPR Think Tank draft IP policy – MSF comments on access and innovation

The IPR Think Tank was convened in November 2014 by Department of Industrial Policy & Promotion (DIPP), Ministry of Commerce, Government of India, to draft a national IPR Policy for India.  Medécins Sans Frontières gives its views on the final version … Continue reading

Posted in Indian Patent Law, IPR policy, IPR Think Tank | 2 Comments

IPR policy to go for Cabinet Approval soon – Commerce Minister

NEW DELHI: In a reaction to the leak of the final draft of India’s new IPR policy on this blog and comments from spicy-ip, Commerce and Industry Minister Nirmala Sitharaman stated last Thursday that the leaked draft policy is not the final version , … Continue reading

Posted in Indian Patent Law, IPR Enforcement, IPR policy, IPR Think Tank | 1 Comment